Investigating the Inhibitory Effect of Isorhamnetin on the Expression of NOXs Genes as well as the Level of ROS in Hepatic Stellate Cells and Its Role in Preventing the Progression of Liver Fibrogenesis

Document Type : Original Article(s)

Authors

1 Assistant Professor, Cellular and Molecular Research Center, Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 PhD, Cellular and Molecular Research Center, Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

3 MSc, Cellular and Molecular Research Center, Department of Hematology, School of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 MSc, Cellular and Molecular Research Center, Department of Clinical Biochemistry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Abstract

Background: Liver fibrosis disease is often attributed to the activation of Hepatic Stellate Cells (HSC) and excessive scarring in the liver. Isoramantin has a protective effect against liver fibrosis by inhibiting the expression of fibrogenic genes caused by Transforming growth factor beta (TGF-β1). In this research, the role of Isorhamnetin in inhibiting the activation of liver stellate cells has been investigated.
Methods: First, the cells were cultured in DMEM culture medium with 10% of Fetal Bovine Serum (FBS) until reaching the appropriate density, and were treated with 75, 100 μM of Isorhamnetin for 24 hours, then the expression levels of NADPH Oxidase (NOX1, NOX2), Collagen1α, alpha-smooth muscle actin (α-SMA) and Reactive oxygen species (ROS) levels were measured to evaluate liver fibrosis.
Findings: The results showed that the expression level of NOX1, NOX2, Collagen1α, and α-SMA genes and the level of ROS in the concentration of 2ng/m of TGF-β increased significantly compared to the control group. Also, in the presence of 75 and 100 μM Isorhamnetin, the expression of these genes and the level of ROS decreased significantly compared to the fibrosis group.
Conclusion: TGF-β increases the expression of genes involved in the progression of liver fibrosis and increases the level of ROS, which increases the production of extracellular matrix, including collagen 1α. Isorhamnetin reduces the expression of genes involved in the development of liver fibrosis. Thus, it can prevent the development of liver fibrosis.

Highlights

Mojtaba Rashidi: Google Scholar, PubMed

Maryam Cheraghzadeh: Google Scholar

Elham Shakerian: Google Scholar

Samaneh Salehipour bavarsad: Google Scholar, PubMed

Keywords

Main Subjects

References

  1. Aydın MM, Akçalı KC. Liver fibrosis. Turk J Gastroenterol 2018; 29(1): 14-21.
  2. Dobie R, Wilson-Kanamori JR, Henderson BE, Smith JR, Matchett KP, Portman JR, et al. Single-cell transcriptomics uncovers zonation of function in the mesenchyme during liver fibrosis. Cell Rep 2019; 29(7): 1832-47. e8.
  3. Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med 2019; 65: 37-55.
  4. Lim BJ, Lee W-K, Lee HW, Lee KS, Kim JK, Chang HY, et al. Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice. Cell Commun Signal 2018; 16(1): 93.
  5. Dewidar B, Meyer C, Dooley S. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019. Cells 2019; 8(11): 1419.
  6. Afarin R, Rezaei HB, Yaghooti H, Mohammadtaghvaei N. Fibroblast Growth Factor 21 Reduces Cholesterol-Induced Hepatic Fibrogenesis by Inhibiting TGF-β/Smad3C Signaling Pathway in LX2 Cells. Hepatitis Monthly 2021; 21(4): e113321.
  7. Afarin R, BABAAHMADI RH, Yaghouti SH, Mohammad TN. The effect of cholesterol on the activation of TGF-β/Smad3C signaling pathway in hepatic stellate cells and its role in the progression of liver fibrogenesis [in Persian]. J Isfahan Med Sch 2021; 39(619): 212-8.
  8. Liu H, Dong F, Li G, Niu M, Zhang C, Han Y, et al. Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways. J Ethnopharmacol 2018; 210: 232-41.
  9. Shakerian E, Akbari R, Mohammadtaghvaei N, Gahrooie MM, Afarin R. Quercetin Reduces Hepatic Fibrogenesis by Inhibiting TGF-β/Smad3 Signaling Pathway in LX-2 Cell Line. Jundishapur J Natural Pharmaceutical Products 2022; 17(1): e113484.
  10. Gong G, Guan Y-Y, Zhang Z-L, Rahman K, Wang S-J, Zhou S, et al. Isorhamnetin: A review of pharmacological Biomed Pharmacother 2020; 128: 110301.
  11. Ganbold M, Shimamoto Y, Ferdousi F, Tominaga K, Isoda H. Antifibrotic effect of methylated quercetin derivatives on TGFβ-induced hepatic stellate cells. Biochem Biophys Rep 2019; 20: 100678.
  12. Rashidi M, Matour E, Nasab HB, Cheraghzadeh M, Shakerian E. Isorhamnetin exerts antifibrotic effects by attenuating platelet-derived growth factor-BB-induced HSC-T6 cells activation via suppressing PI3K-AKT signaling pathway. Iranian Biomed J 2023; 27(4): 199-204.
  13. Mohammadzadeh G, Afarin R, Bavarsad SS, Aslani F, Zadeh SA, Shakerian E. Comparison of the effects of cholesterol, palmitic acid, and glucose on activation of human hepatic stellate cells to induce liver fibrosis. J Diabetes Metab Disord 2022; 21(2): 1531-8.
  14. Afarin R, Behdarvand T, Shakerian E, Bavarsad SS, Rashidi M. Exosomes of Whartons’ jelly mesenchymal stem cell reduce the NOX genes in TGF-β-induced hepatic fibrosis. Iran J Basic Med Sci 2022; 25(12): 1498-503.
  15. Zhao TT, Yang TL, Gong L, Wu P. Isorhamnetin protects against hypoxia/reoxygenation-induced injure by attenuating apoptosis and oxidative stress in H9c2 cardiomyocytes. Gene 2018; 666: 92-9.
  16. Jiang H, Yamashita Y, Nakamura A, Croft K, Ashida H. Quercetin and its metabolite isorhamnetin promote glucose uptake through different signalling pathways in myotubes. Sci Rep 2019; 9(1): 2690.
  17. Ishola IO, Osele MO, Chijioke MC, Adeyemi OO. Isorhamnetin enhanced cortico-hippocampal learning and memory capability in mice with scopolamine-induced amnesia: role of antioxidant defense, cholinergic and BDNF signaling. Brain Res 2019; 1712: 188-96.
  18. Afarin R, Rezaei HB, Yaghouti SH, Taghvaei NM. The effect of cholesterol on the activation of TGF-β/Smad3C signaling pathway in hepatic stellate cells and its role in the progression of liver fibrogenesis [in Persian]. J Isfahan Med Sch 2021; 39(619): 212-8.
  19. Lin L, Gong H, Li R, Huang J, Cai M, Lan T, et al. Nanodrug with ROS and pH Dual‐sensitivity ameliorates liver fibrosis via multicellular regulation. Adv Sci (Weinh) 2020; 7(7): 1903138.
  20. Kim HH, Choi SE, Jeong W-I. Oxidative stress and glutamate excretion in alcoholic steatosis: Metabolic synapse between hepatocyte and stellate cell. Clin Mol Hepatol 2020; 26(4): 697-704.
  21. Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 2020; 9(4): 875.
  22. Liu N, Feng J, Lu X, Yao Z, Liu Q, Lv Y, et al. Isorhamnetin inhibits liver fibrosis by reducing autophagy and inhibiting extracellular matrix formation via the TGF-β1/Smad3 and TGF-β1/p38 MAPK pathways. Mediators Inflamm 2019; 2019.
  23. Ganbold M, Owada Y, Ozawa Y, Shimamoto Y, Ferdousi F, Tominaga K, et al. Isorhamnetin alleviates steatosis and fibrosis in mice with nonalcoholic steatohepatitis. Sci Rep 2019; 9: 16210.
Journal of Isfahan Medical School
Volume 42, Issue 757
1st Week, May
May and June 2024
Pages 113-120

Files

History

  • Receive Date: 20 February 2024
  • Accept Date: 06 June 2024

Share

How to cite

Statistics